Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $9.00 price target on the stock. Needham & Company LLC's price target suggests a potential upside of 156.41% from the stock's previous close.

Autolus Therapeutics Price Performance

NASDAQ AUTL traded down $0.22 on Monday, hitting $3.51. 4,570,103 shares of the stock traded hands, compared to its average volume of 1,422,541. The business's fifty day moving average is $3.99 and its two-hundred day moving average is $4.01. Autolus Therapeutics has a 12 month low of $3.06 and a 12 month high of $7.45. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, research analysts forecast that Autolus Therapeutics will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in Autolus Therapeutics in the third quarter valued at $1,082,000. Privium Fund Management B.V. increased its stake in Autolus Therapeutics by 15.6% in the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company's stock valued at $674,000 after acquiring an additional 25,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after acquiring an additional 14,959 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Autolus Therapeutics by 9.8% during the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock valued at $152,000 after buying an additional 3,740 shares during the last quarter. Finally, Herbst Group LLC bought a new position in shares of Autolus Therapeutics during the third quarter valued at about $91,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.